Loading...
Loading...
KROS| Name | Value |
|---|---|
| Revenues | 18.2M |
| Cost of Revenue | 0.4M |
| Gross Profit | 17.8M |
| Operating Expense | 57.6M |
| Operating I/L | -39.8M |
| Other Income/Expense | 6.9M |
| Interest Income | 0.0M |
| Pretax | -32.9M |
| Income Tax Expense | -2.2M |
| Net Income/Loss | -30.7M |
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's lead protein therapeutic product candidate, KER-050, targets low blood cell counts in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule product candidate for the treatment of anemia, currently in Phase 1 clinical trial, and KER-012, in Phase 1 clinical trial for bone loss disorders and pulmonary arterial hypertension.
